All In Biotech

Drug Trial Radar · NCT00691002

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds

Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,245 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,245

Actual

Start

May 2008

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jun 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous areas (= double-blind phase). Furthermore, the safety and efficacy will be evaluated for up to 60 weeks treatment as required of calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ointment in psoriasis vulgaris on the face and intertriginous areas (= open-label phase).

Conditions

  • Psoriasis Vulgaris

Interventions

  • Calcipotriol plus hydrocortisone (LEO 80190)Drug

    Once daily application

  • LEO 80190 VehicleDrug

  • HydrocortisoneDrug

  • CalcipotriolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind PhaseTime frame: At Week 8 (end of treatment for double-blind phase)

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Croatia - managed by CRO

    Zagreb, Croatia

  • Macedonia - managed by CRO

    Zagreb, Croatia

  • Slovenia - managed by CRO

    Zagreb, Croatia

  • Department of Dermatology and Allergy, University of Bonn

    Bonn, Germany

  • Czech Republic - managed by CRO

    Warsaw, Poland

  • Hungary - managed by CRO

    Warsaw, Poland

  • Latvia - managed by CRO

    Warsaw, Poland

  • Poland - managed by CRO

    Warsaw, Poland

  • Belgium - managed by CRO

    Warsaw, Poland

  • The Netherlands - managed by CRO

    Warsaw, Poland

  • Serbia - managed by CRO

    New Belgrade, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.